Hepatitis G treatment: interferon free or interferon freer?

摘要

To circumvent the disadvantages of interferon, direct-acting antiviral drugs have been developed. The HCV RNA polymerase adds a single ribonucleoprotein triphosphate to the 3' nascent end of the RNA chain.3 There is about 65% homology of the HCV NS5B polymerase across HCV genotypes,4 and the polymerase is thus a potentially pangenotypic antiviral target. Several selective inhibitors of HCV NS5B RNA-dependent RNA polymerase have shown potent in-vitro and in-vivo antiviral activity against HCV.5 Sofosbuvir is a single diastereomer, derived from a 2'-deoxy-2'-fluoro-2/-C-methyluridine prodrug.6 A phosphorami-date moiety improves bioavailability and transport of the nucleotide into hepatocytes to engender high concentrations of uridine nucleoside triphosphate, the active polymerase inhibitor.